Mary Wilson
Well-known member
31 October 2022
https://doi.org/10.1128/mbio.02653-22
Authors: Michael J. Joyner, Nigel Paneth
ABSTRACT
The totality of evidence favors the efficacy of convalescent plasma to treat COVID-19 when high-titer plasma is administered early in the course of disease or to immunocompromised patients. In this commentary, we frame the findings of L. A. Bartelt, A. J. Markmann, B. Nelson, J. Keys, et al. (mBio 13:e01751-22, 2022, https://doi.org/10.1128/mBio.01751-22) in the context of the normal approval process for a therapeutic product. We point out that convalescent plasma has taken all of the typical steps associated with approval for a therapeutic product. Additionally, in less than 3 years, the optimal use cases and continued utility of this product to treat COVID-19 have been defined.
https://journals.asm.org/doi/10.1128/mbio.02653-22#.Y6ICHplOa78.twitter
https://doi.org/10.1128/mbio.02653-22
Authors: Michael J. Joyner, Nigel Paneth
ABSTRACT
The totality of evidence favors the efficacy of convalescent plasma to treat COVID-19 when high-titer plasma is administered early in the course of disease or to immunocompromised patients. In this commentary, we frame the findings of L. A. Bartelt, A. J. Markmann, B. Nelson, J. Keys, et al. (mBio 13:e01751-22, 2022, https://doi.org/10.1128/mBio.01751-22) in the context of the normal approval process for a therapeutic product. We point out that convalescent plasma has taken all of the typical steps associated with approval for a therapeutic product. Additionally, in less than 3 years, the optimal use cases and continued utility of this product to treat COVID-19 have been defined.
https://journals.asm.org/doi/10.1128/mbio.02653-22#.Y6ICHplOa78.twitter